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Carcinoma of the uterine cervix is a common malignancy affecting
adult women worldwide, especially in developing countries.
Epidemiological studies have suggested multiple risk factors in its
aetiology (Wahi et al, 1969; Murthy et al, 1990; Howley, 1991).
Inactivation or deletion of multiple tumour-related genes, which
regulate normal cellular growth and suppression of abnormal cell
proliferation, is recognized to be one of the major mechanisms of
tumorigenesis. Mutations or deletions in the tumour-related genes
are frequently accompanied by loss of the remaining allele or alleles
(loss of heterozygosity, LOH), leading to homozygous inactivation
of the gene(s) (Manchall, 1991; Hampton et al, 1994; Chridhar et al,
1996). Several studies have shown that LOH at specific chromo-
somal sites is frequently associated with the development of various
cancers (Manchall, 1991). Some studies of cervical carcinoma have
shown LOH on chromosome 11p, suggesting the presence of candi-
date tumour-suppressor genes on that chromosome (Busby-Earle, et
al, 1993; Mitra et al, 1994). Recently, a gene, TSG101, was isolated
and mapped to chromosome 11p15.1—15.2, a region proposed to
contain tumour-suppressor genes that is mutated at high frequency
in human breast cancer (Li and Cohen, 1996; Li et al, 1997).
Because the LOH region in cervical carcinoma is close to the
TSG101 area, we analysed the mutation frequency of the TSG101
gene in cervical and endometrial carcinomas, to investigate the role
of TSG101 in the development of both tumours. We also evaluated
the relationship between the human papilloma infection and the
transcripts of TSG101.
MATERIALS AND METHODS
Specimens
Tissue samples from primary tumours and nearby non-tumorous
tissue samples were obtained from five patients with endometrial
cancer and 19 with cervical carcinoma who had been treated at
Mackay Memorial Hospital (Taipei, Taiwan). All tissue samples
were confirmed histologically. Clinically, two cases of endome-
trial cancer were stage Ib, and three were stage IIa. All these were
adenocarcinoma. Of the cases of cervical cancer, eight were stage
Ib, seven were IIa, two were IIb, and one case each was stage III or
IV. All the cervical cancer cases were squamous cell carcinoma, 13
cases were well to moderately differentiated and six poorly differ-
entiated. The proportion of tumour cells varied from 60% to 90%.
The age of the patients ranged from 31 to 80 years old with a mean
of 51 years. Peripheral mononuclear cells from 16 healthy persons
were used as a normal control.
DNA, RNA extraction and reverse transcription
Tumour specimens were frozen immediately after surgical resec-
tion and stored in liquid nitrogen until extraction of DNA or RNA.
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Summary Carcinoma of the uterine cervix is a common malignancy among women that has been found to show loss of heterozygosity in the
chromosome 11p. Recent studies have localized the TSG101 gene in this region, and also demonstrated a high frequency of abnormalities of
this gene in human breast cancer. To determine the role of the TSG101 gene in the carcinogenesis of cervical and uterine carcinoma, 19
cases of cervical carcinoma and five cases of endometrial carcinoma, as well as nearby non-cancerous tissue from the same patients, and 16
blood samples from healthy persons as normal control were analysed by Southern blot analysis of genomic DNA, reverse transcription of the
TSG101 mRNA followed by PCR amplification and sequencing of the products. We found that abnormal transcripts of the TSG101 gene were
common both in cancerous or non-cancerous tissues of the uterus and cervix and in normal peripheral mononuclear cells. There was no
genomic deletion or rearrangement in spite of the presence of abnormal transcripts, and no definite relationship between the abnormal
transcripts and HPV infection was found. Although the frequency of abnormal transcripts was higher in cancerous than in non-cancerous
tissue, normal peripheral mononuclear cells also had abnormal transcripts. Given these findings, the role of the TSG101 gene as a tumour-
suppressor gene should be re-evaluated. Because some aberrant transcripts could be found at the first PCR reaction, we suggest that the
aberrant transcripts might be the result of imperfect minor splicesome products.
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This study had been presented as a poster at the 47th Annual Meeting of the
American Society of Human Genetics. Drs JG Chang and TH Su have made equal
contributions to this study.The DNA extraction was performed as previously described (Lin
et al, 1993). Total RNA was purified from cancerous and nearby
non-cancerous tissues and peripheral mononuclear cells using a
commercial kit (RNAzolTMB, Biotecx laboratories, Houston, TX,
USA). RNA was stored as a pellet in ethanol or solubilized in
RNAase-free water and kept at —70°C. Reverse transcription was
performed as described previously (Chen et al, 1997).
Reverse transcription polymerase chain reaction
(RT-PCR), long PCR, Southern blot analysis and
sequencing
The primers used for RT-PCR analysis of the TSG101 gene are
shown in Table 1. The PCR conditions were as described, but with
some modifications (Chen et al, 1997). Briefly, 1 ml of cDNA was
used for the first PCR amplification in a volume of 100 ml
446 J-G Chang et al
British Journal of Cancer (1999) 79(3/4), 445–450 © Cancer Research Campaign 1999
Table 1 Oligonucleotide primers for study of the TSG101 gene
Primers Sequences cDNA locationa
First RT-PCR
P1u 5¢-AGCCCAGCAGCGGCTGACCCTCT-3¢ nt 35–57
P1d 5¢-CTTATTCTGGGCACCTACTGAT-3¢ nt 1342–1321
Second RT-PCR
P2u 5¢-CGGTGTCGGAGAGCCAGCTCAAG-3¢ nt 95–117
P2d 5¢-CTCAACCTCCAGCTGGTATC-3¢ nt 1290–1271
For sequencing
Ad 5¢-AGTAGCCATAGGCATATTTGG-3¢ nt 320–301
Bu 5¢-GCCTTATAGAGGTAATACATAC-3¢ nt 273–294
Bd 5¢-ATAGGATGCCGAAATAGGAC-3¢ nt 540–521
Cu 5¢-CTTCCTTATCTACATGAATGG-3¢ nt 421–441
Cd 5¢-CACCAGGTGGGTAAGGACAG-3¢ nt 670–651
Du 5¢-GATACCCTCCCAATCCCAGTG-3¢ nt 620–640
Dd 5¢-TTCGTTTCAAGGCATTGAGC-3¢ nt 865–846
Eu 5¢-ATCTCTGCGGTCAGTGACA-3¢ nt 781–799
Ed 5¢-AGGGAGCTGTGGGAATGATA-3¢ nt 1060–1041
Fu 5¢-GGAAAAAATGGAAAATCAGTCTG nt 996–1018
aAccording to nucleotide sequence of TSG101 cDNA (GenBank accession number U82130). nt, nucleotide.
Table 2 Aberrant transcripts of TSG101 in cervical cancer
Case Age Pathological Abnormal transcript
finding
Tumour HPV Non-tumour HPV
1 35 SCC/II IB1,IA1 +– +
3 56 SCC/III IB1,IA4 – ID,IA1,IA4 –
4 42 SCC/III IA1,IB2,IIB,IA3 –– –
5 28 SCC/II IA3,IA1 +I A 1,IC,IID +
6 67 SCC/III IB2,IIL + IID +
8 36 SCC/II IB2,IIB,IA3 +I B 2,IA1 +
9 31 SCC/II IB1,IB2 + IIH +
13 59 SCC/III IB2,IA1 +I A 1 +
14 36 SCC/II IE + IIM +
15 73 SCC/II IB2,IIK,IA1 – II I,IID –
16 63 SCC/II IB2 +– –
17 67 SCC/II IA1,IA4 –– –
18 50 SCC/III IIM + IA4 +
19 48 SCC/II IID,IA1,IIA + IIF,IA1 +
20 48 SCC/III IE,IB2,IA,IIF + IE,IA1 +
21 35 SCC/II IB2,IID + IIF,IIE,IB1,IIA,IA1,IA4 +
22 56 SCC/III IID,IE,IB2,IB1,IA1,IA4, + IE,IB2,IIA, IA1,IA4,IIJ +
23 48 SCC/II IB2,IB1,IIK,IA1 +I A 2,IIM +
24 55 SCC/II IE,IB2,IA,IA4 +– +
IA1, nt 132–729 deletion; IA2, nt 132–637 deletion; IA3, nt 133–933 deletion; IA4, nt 133–447 deletion; IB1, nt 154–1054 deletion; IB2, nt 154–1070 deletion;
IC, nt 166–1113 deletion; ID, nt 172–1194 deletion; IE, nt 230–1212 deletion; IF, nt 284–638 deletion; IIA, nt 120–873 deletion; IIB, nt 125–1007 deletion;
IIC, nt 145–1072 deletion; IID, nt 150–1157 deletion; IIE, nt 151–1102 deletion; IIF, nt 160–1182 deletion; IIG, nt 184–1259 deletion; IIH, nt 200–959 deletion;
II I, nt 250–1221 deletion, IIJ, nt 262–1160 deletion; IIK, nt 335–1152 deletion; IIL, nt 399–1178 deletion; IIM, nt 443–830 deletion; IIN, nt 687–1112 deletion;
nt, nucleotide; SCC, squamous cell carcinoma.containing 100 ng each of primers P1u and P1d, 50 mM of each
dNTP, 1 ´ PCR buffer, and 2.5 units polymerase. PCR was per-
formed for 35 cycles of 1.5 min at 94°C for denaturation, 1.5 min
at 56°C for annealing, and 2.5 min at 72°C for extension, with a
final extension of 5 min at 72°C using a Perkin-Elmer Cetus PCR
Thermocycler. Of the first PCR products, 1—10 ml were subjected
to a second round of PCR amplification using nested primers P2u
and P2d for 35 cycles under the above conditions. The PCR prod-
ucts were electrophoresed and analysed using agarose gel. For
long PCR, amplification of genomic DNA, the primers and PCR
conditions were identical to the study of Li et al, 1997). We also
used the primer located near the breakpoint regions to amplify the
breakpoints (Table 1). The PCR products of nested RT-PCR and
long PCR were subjected to Southern blot analysis as follows: the
DNA on agarose gel was Southern transferred to a nylon
membrane. The membrane was hybridized with a random-primer
32P-labelled probe (DECA primer II DNA labelling kit, Ambion,
Austin, TX, USA) which corresponded to the cDNA of TSG101.
All positively labelled fragments were subjected to isolation and
sequencing analysis. Isolation was achieved by electrophoresis in
a 3% low melting agarose gel; the fragments were excised after
separation. They were then purified using a commercial kit (Qiaex
II gel extraction kit, Qiagen, Chatsworth, CA, USA), and the
purified fragments were sequenced by the cycling sequencing
method using an ABI 310 automatic sequencer. The sequencing
primers are also shown in the Table 1.
Southern blot analysis of genomic DNA
Genomic DNA (5—10 mg) was digested with restriction enzymes
EcoRI, HindIII and SacI according the manufacturer￿s instruc-
tions, electrophoresed in 0.8% agarose gel, Southern transferred to
Hybond H+ membrane, fixed by UV cross-linking, and the
membrane was hybridized with a random-primer 32P-labelled
cDNA probe as mentioned above. Loss or gain of restriction frag-
ments was assessed by visual comparison of hybridization signals
after developing the exposed radiographic film.
Human papillomavirus (HPV) analysis
The HPV DNA sequence in tumour samples was amplified using
the pU-1M/PU-2R primer pair to amplify malignant HPV DNA
(HPV 16, 18, 31, 33, 52b and 58); benign HPV DNA (HPV 6 and
11) was amplified using the pU-31B/pU-2R primer pair. The
primers and PCR procedures were identical to those used in the
study of Fujinaga et al (1991).
RESULTS
RT-PCR amplification and sequence analysis
RT-PCR analysis and sequencing of the PCR fragments revealed
frequent expression of both the wild-type TSG101 and intragenic
deletions in cancerous and non-cancerous tissues. The results of
TSG101 in cervical and endometrial cancers 447
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Figure 1 Nested RT-PCR amplification of TSG101 from cervical and endometrial cancer tissues (A, B, C). Cases 2, 7, 10, 11 and 12 were from cases of
endometrial cancer. The rest were cervical cancer. C, cancerous tissue. N, non-cancerous tissue. The results of peripheral mononuclear cells are shown in D.
L, peripheral mononuclear cells. The 1196-bp band is the normal TSG101 gene transcript. The smaller bands are aberrant transcriptsabnormal transcript analysis are shown in Figures 1(A—C) and 2.
In addition to the wild-type transcript, most cancerous tissues
(100% of cervical carcinomas and 80% of endometrial carci-
nomas) as well as most of the non-cancerous tissues (73.7% of
nearby cervical tissues and 80% of paired endometrial tissues)
demonstrated one or more aberrant TSG101 transcripts (Figure 1).
The aberrant band sizes were diverse (120—881 bp) with a range of
one to six bands in any one specimen. Upon sequencing, we found
that the aberrant bands were due to intragenic deletions, including
25 different types of deletion and deletion sizes range from 387 bp
to 1075 bp. According to region, at least three major categories of
deletion could be found. Group 1 was similar to those found by
Lee and Feinberg (1997), and may be due to relaxation of the
splicing mechanism (Figure 3, type 1). Group 2 had a common
homologous sequence between the donor and acceptor area
(Figure 3, type II). Group 3 had a deletion and an insertion (Figure
3, type III). Cancerous and non-cancerous tissues did not differ in
the types of deletions found. The sequencing results of aberrant
bands are shown in Table 2 and Figure 2.
Genomic long PCR and genomic Southern blot
analysis
For further analysis of the breakpoint, we followed long PCR
method as described by Li et al (1997). At the expected breakpoint
site on the gel, no PCR products could be found with TSG101
448 J-G Chang et al
British Journal of Cancer (1999) 79(3/4), 445–450 © Cancer Research Campaign 1999
Type I
CC C C CC A A A TT T GGG GG
110 120
730131
132–729 A1
Type II
C C C A A T T GG
280 290
874119
120–873 A
TC TT G T GG
A TT G
30 140
1055153
154–1054 B1
G G G GG G AA A A T T
A
40
1114 165
166–1113 C
G A T AA G A TTTCC AG
140 150
1007124
125–1007 B
T GAC T T T CA TT T T CTT G GA
100
1073 144
145–1072 C
T C AG TT T A T T T CA G GG T
110
Type III. Deletion of loci 132–732 with the insertion of 37 bp
C A
110
733
G TT T GG C ACA AT G G T TA C TT C
130 120 140
T T CC C A G T A T T
150
C A G G TT C TAA CTT TA
131 insertion of 37 bp
Figure 2 Sequence at TSG101 cDNA deletion junction in representative cases of cancerous and non-cancerous tissues and normal peripheral mononuclear
cells. Numbers above each figure indicate abnormal junction between deletions
Type I. Splicing donor or acceptor site-like sequence near the deletion junction.
Example: deletion from cDNA 154 to 1070
5'-......AGACCTAACTGTACGTGAAA......-3' Donor site
Acceptor site 5'-......ATACAAACAGATCCTGAATC......-3'
Type II Homologous sequences at deletion junction.
Example: deletion from cDNA 120 to 873
Donor site
Acceptor site
 5'-......AGCTCAAGAAAATGGTGTT......-3'
5'-....AACAGAAGAAGACCTGAAA......-3'
Type III Deletion and insertion.
Example: deletion from cDNA 132 to 732 and insertion of 37 bp
5'......AGGTTCAATA...insertion 37 bp...ACTGGGTCAT......-3'
153 154
donor site-like sequence
10701071
119120
deletion
873 874
131 733
deletion
Figure 3 Sequencing analysis of aberrant RNA splicing. There are three
types of aberrant transcripts. Type I has a splicing donor or acceptor site
sequence at the deletion junction region. Type II has a homologous
sequence between the deletion junction region. Type III has both deletion
and insertioncDNA probe detection (data not shown). We also used primers
much closer to the intragenic deletion region to amplify the break-
point. However, we were unable to amplify the breakpoint region.
To further demonstrate gross deletion of the TSG101gene, we
used Southern blot analysis of genomic DNA to detect deletion
fragments. There were no gross deletions despite the presence of
aberrant transcripts (data not shown). The lack of any altered DNA
fragment on direct genomic Southern blots and long PCR analysis
in any of the 19 cervical and five endometrial cancerous or non-
cancerous samples, including those with aberrant transcripts, indi-
cated that the aberrant transcripts were not caused by intragenic
deletion of sufficient size to explain them.
HPV analysis
None of the patients in this study with endometrial cancer had
HPV infection. Of 19 patients with cervical cancers (73.7%), 14
had detectable HPV DNA, of which 11 were HPV 16, two HPV
18, one HPV16+31, one HPV 31, and one HPV 58. Of 18 non-
cancerous tissues, ten demonstrated HPV infection, of which five
tissues were infected by HPV 16, one by HPV 18, and four by
HPV 31. However, no definite relationship between HPV infection
and the abnormal TSG101transcript was found (Table 2).
Aberrant transcripts of TSG101in normal peripheral
mononuclear cells
RT-PCR analysis and sequencing of the PCR fragments in normal
peripheral mononuclear cells revealed frequent expression of the
wild-type and intragenic deletion of TSG101transcripts. The
results of abnormal transcript analysis are shown in the Figure 1D
and Table 2. In addition to the wild-type transcript, 9 (56.25%) out
of 16 demonstrated one to four aberrant TSG101transcripts
(Figure 1D).
DISCUSSION
Li et al (1997), based on the presence of truncated transcripts found
by RT-PCR and Southern hybridization of PCR products of genomic
DNA, reported the presence of large intragenic deletions of the
TSG101gene in 7 out of 15 primary human breast cancers, but none
in matched normal breast tissues. Lee et al (1997) used a similar
approach to analyse 72 human breast cancer and matched non-
cancerous tissues. They found that the aberrant transcripts were
common in both cancerous and non-cancerous tissues; no intragenic
deletions were found in their cases using long PCR or Southern blot
analysis of genomic DNA. Steiner et al (1997) performed Southern
blot analysis of genomic DNA from human breast cancer cell lines
and normal peripheral blood. They were unable to find intragenic
deletion of TSG101gene. In this study, we used a similar approach
to investigate the role of TSG101in the development of cervical and
endometrial cancers. We also found that the aberrant transcripts
were common in both cancerous and non-cancerous tissues, and that
there were no intragenic deletions, point mutations or small dele-
tions/insertions on genomic Southern blot analysis and whole cDNA
sequencing analysis. Our results were, thus, similar to the studies of
Lee et al (1997) and Steiner et al (1997).
Lee et al (1997) suggested that the relaxation of RNA splicing
may, in general, contribute to abnormal gene expression. We found
a new type of aberrant transcript that had a homologous sequence
between donor and acceptor sites. We suggest that this type of
aberrant transcript may be related to RNA secondary structure. We
found some aberrant transcripts could be found at the first PCR
reaction, such as deletion from nucleotide 154 to 1054 or from
nucleotide 154 to 1070, which has highly homologous splicing and
acceptor site-like sequence at the deletion junction. From this
point of view, we suggest that the aberrant transcripts might be the
result of imperfect minor splicesome products.
The aberrant splicing of TSG101gene appears to be identified
more frequently in cancerous than in non-cancerous tissues (100%
vs. 72.5%), but it also appears in peripheral mononuclear cells of
normal persons. For these reasons, the role of TSG101gene as a
tumour-suppressor gene cannot yet be confirmed and requires
much more careful evaluation.
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